{
    "nctId": "NCT02560311",
    "briefTitle": "Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis",
    "officialTitle": "Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis",
    "overallStatus": "UNKNOWN",
    "conditions": "ERBB2, Breast Cancer, Metastatic Neoplasm",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Time to disease progression",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Received at least 1 dose of trastuzumab in metastatic setting at the University hospital of Zurich from 01/2004 to 12/2014.\n* HER2+ status confirmed by immunohistochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) \u2265 2.\n\nExclusion Criteria:\n\n-",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}